Top Markets
#1 Talus Network Talus Network +31.64%
#2 Starpower Starpower +31.04%
#3 Brevis Brevis +30.27%
#4 Keep Network Keep Network +29.44%
#5 Tung Tung Tung Sahur Tung Tung Tung Sahur +25.54%
#6 MemeCore MemeCore +24.60%
#7 Infinity Ground Infinity Ground +22.45%
#8 Allora Allora +21.35%
#9 屎壳郎 (Dung Beetle) 屎壳郎 (Dung Beetle) +17.45%
#10 DeepBook DeepBook +17.40%
Coin of the day
Talus Network Talus Network
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
IntegraGen SA IntegraGen SA

IntegraGen SA

ALINT
Peringkat dalam Saham #19673
IntegraGen SA provides human genome analysis services for academic researcher... IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.
Harga Saham
$0.20876331
Kapitalisasi Pasar
$1.38M
Perubahan (1 hari)
1.15%
Perubahan (1 tahun)
-64.84%
Negara
FR
Perdagangan IntegraGen SA (ALINT)

Kategori

Healthcare
Pendapatan untuk IntegraGen SA (ALINT)
Pendapatan pada Dec 2025 TTM: $5.89M
Menurut laporan keuangan terbaru dari IntegraGen SA, pendapatan saat ini (TTM) adalah $5.89M. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar $13.86M penurunan dibandingkan dengan pendapatan pada tahun 2022 yang sebesar $14.12M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan IntegraGen SA dari 2008 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) $5.89M -34.91%
2024 $9.05M -34.70%
2023 $13.86M -1.87%
2022 $14.12M 9.68%
2021 $12.88M 17.75%
2020 $10.94M 17.72%
2019 $9.29M 16.30%
2018 $7.99M 2.28%
2017 $7.81M 18.34%
2016 $6.60M 5.01%
2015 $6.28M -15.26%
2014 $7.42M -0.36%
2013 $7.44M 19.02%
2012 $6.25M 3.91%
2011 $6.02M 36.01%
2010 $4.43M 9.71%
2009 $4.03M 28.07%
2008 $3.15M 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $52.05B 883,391.72%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B 207,933.89%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B 253,164.55%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 154,074.16%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.29B 106,681.86%
NL